Polynovo Ltd represents a strong set of values and an innovative corporate philosophy. The company is committed to delivering advanced medical solutions using their unique NovoSorb® technology platform. Polynovo focuses on improving patient outcomes by providing safe and effective products for the healthcare industry. Their dedication to research and development allows them to create cutting-edge solutions that address critical needs in wound healing and soft tissue repair. With a customer-centric approach, Polynovo strives to make a positive impact on healthcare by offering innovative products and maintaining high standards of quality, safety, and ethics.

Polynovo Ltd is primarily present in Australia and the United States.

Polynovo Ltd has achieved several significant milestones in recent years. First and foremost, the company successfully developed and commercialized its innovative NovoSorb BTM technology. This breakthrough technology has revolutionized the treatment of complex wounds, allowing for faster and more effective healing. Another notable milestone for Polynovo Ltd was its expansion into international markets, securing regulatory approvals in Europe, the United States, and other key regions. Additionally, the company has formed strategic partnerships with global healthcare companies, further strengthening its position in the market. These achievements demonstrate Polynovo Ltd's commitment to providing cutting-edge solutions for wound care management and its continuous growth in the industry.

Polynovo Ltd is an Australian medical device company specializing in the design, development, and manufacturing of dermal regeneration solutions. Established in 1998, Polynovo has become a global leader in its field, with its flagship product NovoSorb® BTM gaining significant recognition. This innovative biodegradable scaffold facilitates the regeneration of full-thickness skin and helps treat various wounds, burns, and surgical incisions. Polynovo's commitment to advanced technology, research, and development has enabled them to establish a strong presence in international markets, providing medical professionals and patients with effective and lasting solutions for improved healing outcomes.

The main competitors of Polynovo Ltd in the market include larger medical device companies such as Johnson & Johnson, Medtronic, and Zimmer Biomet. These companies also offer innovative and competitive products in the field of medical device manufacturing. However, Polynovo Ltd distinguishes itself with its unique patented NovoSorb platform, which is highly regarded for its biocompatible and bioresorbable capabilities. Polynovo Ltd aims to revolutionize the market with its innovative medical solutions, providing patients with advanced options for wound care and tissue repair.

Polynovo Ltd is primarily active in the medical industry, specifically specializing in the development, manufacturing, and commercialization of medical devices. The company's innovative technologies focus on the treatment of acute and chronic wounds, including burns, surgical wounds, and skin defects. Polynovo's products, such as its leading NovoSorb BTM technology, offer surgeons and patients advanced wound healing solutions. With a strong commitment to research and development, Polynovo aims to cater to the growing global demand for effective wound care and tissue regeneration products.

The business model of Polynovo Ltd, an Australian medical device company, is centered around the development, manufacturing, and commercialization of its innovative biodegradable polymer technologies for the medical industry. Polynovo's core product is NovoSorb, a revolutionary biomaterial that can be used in various medical applications, such as wound management, surgical procedures, and tissue regeneration. By harnessing the benefits of NovoSorb, Polynovo aims to provide healthcare professionals with advanced solutions that improve patient outcomes and reduce healthcare costs. With its focus on research, technology, and collaboration, Polynovo Ltd strives to establish itself as a leading player in the global medical device market.

Polynovo의 P/E 비율은 275.09입니다.

Polynovo의 P/S 비율은 13.82입니다.

Polynovo에 대한 AlleAktien 품질 점수는 4/10입니다.

Polynovo 매출은 104.73 백만 AUD입니다.

Polynovo 이익은 5.26 백만 AUD입니다.

Polynovo Ltd is an Australian company specializing in the manufacture of medical products. The company's business model is based on offering various products divided into three main areas: wound care, surgery, and traumatology. Polynovo develops innovative and advanced medical products for wound healing, surgery, and traumatology. The company uses bioresorbable materials to accelerate the healing process and reduce the risk of infections. Polynovo invests significant resources in research and development to maintain technological leadership in this field. The company sells its products directly to hospitals, healthcare providers, wound healing and surgery professionals. Polynovo aims to expand its reach and enter new markets to promote business growth. The company's business model is focused on solving people's health issues and enabling a better life.

Polynovo은(는) 연간 번의 배당을 통해 0 AUD의 배당금을 지급합니다.

Polynovo의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Polynovo의 ISIN은 AU000000PNV0입니다.

Polynovo의 WKN은 A12F4T입니다.

Polynovo의 티커는 PNV.AX입니다.

지난 12개월 동안 Polynovo은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Polynovo은(는) 0 AUD의 배당금을 지급할 것으로 예상됩니다.

Polynovo의 현재 배당 수익률은 입니다.

Polynovo은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Polynovo은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 AUD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Polynovo은 '건강' 섹터에 속합니다.

Polynovo의 마지막 배당금을 0 AUD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Polynovo는 0 AUD를 배당금으로 지급했습니다.

Polynovo의 배당금은 AUD에 지급됩니다.